British drug regulator National Institute for Health and Clinical Excellence (NICE) has approved the use of the anti-clotting drug manufactured by Pfizer and Bristol-Meyers, apixaban, in preventing blood clots post hip and knee surgery.
NICE said that apixaban, which is being marketed under the brand name Eliquis, was a cost effective and clinically effective option in treating blood clots.
AdvertisementThe treatment for knee replacement patients will last for 12 days and will cost around £41.16 while it will last for 34 days for hip replacement patients and will cost £116.62.
P Man Accuses Ex-Girlfriend of Stealing Sperm Evangelical Churches’ Claims of Healing HIV Probed in Undercover Investigation M
You May Also Like